Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AGNPF source : Www.biospace.com save search
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
Published: 2023-11-30 (Crawled : 17:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 12.32%
H: 0.0%
C: 0.0%
patent treat pharmaceuticals grant chinese nash
Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
Published: 2023-04-20 (Crawled : 12:20) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 0.9%
H: 11.11%
C: 11.11%
offering pharmaceuticals
Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application
Published: 2023-04-17 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -1.08%
H: 12.66%
C: 4.75%
patent pharmaceuticals application
Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
Published: 2023-04-04 (Crawled : 17:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 3.21%
H: 29.32%
C: -3.11%
study
Algernon Pharmaceuticals Announces Launch of Rights Offering
Published: 2023-03-21 (Crawled : 14:20) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -4.08%
H: 0.0%
C: -8.74%
offering pharmaceuticals
Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board
Published: 2023-01-11 (Crawled : 14:20) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -2.94%
H: 2.42%
C: 1.68%
pharmaceuticals
Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil Ifenprodil Represents a Novel First-in-Class Potential Treatment for Chronic Cough
Published: 2023-01-09 (Crawled : 21:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -4.07%
H: 0.0%
C: 0.0%
treatment pharmaceuticals potential study phase 2b
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-12-05 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 21.05%
H: 0.0%
C: -4.78%
treatment fda fibrosis pharmaceuticals designation drug
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
Published: 2022-10-24 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: -0.93%
pharmaceuticals trial agreement depression study phase 2
Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference
Published: 2022-10-14 (Crawled : 15:20) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
pharmaceuticals ceo conference
Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
Published: 2022-09-19 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -3.64%
H: 4.85%
C: 4.85%
treatment fda designation
Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position
Published: 2022-08-23 (Crawled : 12:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 7.69%
H: 12.89%
C: 7.45%
management
Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
Published: 2022-08-03 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -4.93%
conference study phase 2
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 0.12%
H: 1.62%
C: 1.62%
positive study phase 2
Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough
Published: 2022-07-18 (Crawled : 14:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 1.48%
H: 8.75%
C: 6.25%
fibrosis study phase 2
Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
Published: 2022-06-22 (Crawled : 14:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 34.22%
H: 0.0%
C: 0.0%
treatment fibrosis patent
Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended
Published: 2022-06-21 (Crawled : 19:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 2.48%
H: 0.0%
C: -6.35%
ongoing phase 2
Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough
Published: 2022-06-13 (Crawled : 13:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: 3.66%
H: 0.36%
C: 0.36%
phase 2
Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study
Published: 2022-04-26 (Crawled : 13:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -8.89%
H: 0.0%
C: 0.0%
fibrosis drug disease preclinical kidney nash pre-clinical
Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
Published: 2022-02-04 (Crawled : 15:00) - biospace.com/
AGNPF | $0.0708 178.69% 1.3K
|
Health Technology
|
| O: -3.69%
H: 1.03%
C: -3.33%
phase 2 als chronic cough enroll
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.